Skip to main content
CATX
NASDAQ Life Sciences

Perspective's VMT-α-NET Shows 75% 18-Month PFS in SSTR2+ GEP-NETs; End-of-Phase 2 Targeted 1Q 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.82
Mkt Cap
$89.997M
52W Low
$0.781
52W High
$6.16
52W Position info
4.9% above low
Off High info
87% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

CATX is trading near its 52-week low of $0.781 (4.9% above the low).

Summary

Perspective presented incremental Phase 1/2a data showing 75% 18-month PFS and 37-47% response rates in SSTR2+ GEP-NET patients, with a clean safety profile, and said it is targeting an End-of-Phase 2 FDA meeting in 1Q 2027 ahead of a 2027 Phase 3 start.


Key Events · Product Development and Regulatory · CATX

  • NANETS Data Show Durable PFS

    Across Cohorts 1-3, the 57 GEP-NET patients with SSTR2 expression in all target lesions showed PFS of 91% at 6 months, 78% at 12 months and 75% at 18 months.

  • Response Rates in SSTR2+ Subgroup

    Objective response rate was 37% (14 of 38) in Cohort 2 and 47% (8 of 17) in Cohort 3; disease control was 92% and 100%, respectively.

  • Clean Safety Across 68 Patients

    No dose-limiting toxicities, no Grade 4 or 5 treatment-emergent events and no treatment-related discontinuations; Grade 3 events occurred in 20 of 68 patients (29%).

  • End-of-Phase 2 Meeting Targeted 1Q 2027

    The company is incorporating the SSTR2-enriched population into FDA discussions and targets an End-of-Phase 2 meeting in the first quarter of 2027, with Phase 3 initiation expected in 2027.


Analysis · CATX · Life Sciences

The NANETS dataset offers the clearest efficacy read yet for Perspective's lead radiopharmaceutical. Among the 57 GEP-NET patients whose target lesions all express SSTR2, 75% remained progression-free at 18 months, versus roughly 65% at 18 months for the approved lutetium-177 benchmark cited in its U.S. label; objective responses occurred in 37% (Cohort 2) and 47% (Cohort 3) of that subgroup. Safety held up, with no dose-limiting toxicities, no Grade 4 or 5 treatment-emergent events and no treatment-related discontinuations across 68 treated patients. Perspective now says it is folding this SSTR2-enriched population into regulator discussions and targeting an End-of-Phase 2 meeting in the first quarter of 2027, with Phase 3 initiation expected in 2027. That makes the next hard checkpoint a regulatory one, and the stock — trading near its 52-week low — is priced for execution risk on a program that still needs cash to reach a registrational trial.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CATX was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90M. The 52-week trading range was $0.78 to $6.16. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CATX - Latest Insights

CATX
Nov 09, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.860
Real-time Price: $0.750 info
Change: -$0.110 (-13%) info
Market Cap: $91.028M info
CATX
Nov 06, 2026, 12:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.85005
Real-time Price: $0.750 info
Change: -$0.10005 (-12%) info
Market Cap: $91.028M info